Organigram Global (OGI) Operating Leases (2023 - 2024)
Organigram Global (OGI) posted quarterly Operating Leases of $2.5 million for Q3 2024, down 28.0% year-over-year from $3.4 million in Q4 2023, and down 28.0% quarter-over-quarter from $3.4 million in Q3 2023.
Organigram Global (OGI) Operating Leases (2023 - 2024) Analysis & Trends
Organigram Global (OGI) has reported Operating Leases for 2 consecutive years, with $2.5 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Operating Leases fell 28.0% year-over-year to $2.5 million; the TTM figure through Sep 2024 stood at $2.5 million (down 28.0% YoY), while the FY2024 annual figure was $2.5 million, down 28.0% from the prior year.
- Operating Leases fell to $2.5 million in Q3 2024 per OGI's latest filing, from $3.4 million in the prior quarter.
- Across five years, Operating Leases topped out at $3.4 million in Q3 2023 and bottomed at $2.5 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Organigram Global | 150.66 Mn | 150.54 Mn | 28.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.45 Mn |
| Sep 30, 2023 | 3.40 Mn |